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ABSTRACT  26 
 27 
BACKGROUND: Mycobacterium asiaticum was first reported as a cause of human 28 
disease in 1982, with only a few cases in the literature to date.  This study aims to 29 
review the clinical significance of M. asiaticum isolates in Queensland. 30 
METHODS: A retrospective review (1989-2008) of patients with M. asiaticum 31 
isolates was conducted. Data was collected through the Queensland TB Control 32 
Centre database. Disease was defined in accordance with the American Thoracic 33 
Society criteria.  34 
RESULTS: Twenty four patients (13 Female) had a positive culture of M. asiaticum, 35 
many residing around the Tropic of Capricorn.  M. asiaticum was responsible for 36 
pulmonary disease (n=2), childhood lymphadenitis (n=1), olecranon bursitis (n=1), 6 37 
cases of possible pulmonary disease and 2 possible wound infections. Chronic lung 38 
disease was a risk factor for pulmonary infection, and wounds/lacerations for 39 
extrapulmonary disease. Extrapulmonary disease responded to local measures. 40 
Pulmonary disease responded to ethambutol/isoniazid/rifampicin, plus pyrazinamide 41 
for the first two months in one patient, and amikacin/azithromycin/minocycline in 42 
another patient. 43 
CONCLUSION: Whilst M. asiaticum is rare in Queensland, there appears to be an 44 
environmental niche. Although often a colonizer, it can be a cause of pulmonary and 45 
extrapulmonary disease. Treatment of pulmonary disease remains challenging. 46 
Extrapulmonary disease does not mandate specific NTM treatment.  47 
 48 
 49 
 50 
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 51 
INTRODUCTION 52 
 53 
Non tuberculous mycobacteria (NTM) have been recognized as human pathogens 54 
since the 1950’s. (17, 30) Over recent decades the taxonomy has continued to evolve 55 
and new species are being recognized. This is attributable to improved methods of 56 
identification, including chemotaxonomic and molecular methods.(11) 57 
 58 
M. asiaticum was first named by Weiszfeiler et al who recognized it as a new slow 59 
growing mycobacterium species with separate characteristics from Mycobacterium 60 
simae and the other slow growers Mycobacterium kansasii and Mycobacterium 61 
marinum.(31) It was first reported in humans in Queensland (QLD) by Blacklock in 62 
1982, where M. asiaticum was thought to be responsible for pulmonary disease in 2 of 63 
5 human cases.(5) The first case report of pulmonary disease secondary to M. 64 
asiaticum in the USA was in 1990.(27) These reported patients with progressive 65 
pulmonary disease secondary to M. asiaticum, mostly had an underlying chronic 66 
respiratory problem such as COPD. M. asiaticum has also been reported to be 67 
responsible for extrapulmonary disease in humans namely flexor tenosynovitis,(8) 68 
olecranon bursitis, (6) and keratitis. (7) 69 
 70 
Previous studies with their limitations, have suggested climate as a factor responsible 71 
for the distribution of M. asiaticum, with an association noted between prevalence of 72 
M. asiaticum and subtropical climates, such as Queensland’s, particularly an area of 73 
northern Queensland known as the Tropic of Capricorn.(5) This association was noted 74 
in both animal and human studies.(31) 75 
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 76 
There is limited data about the antimicrobial susceptibilities of M. asiaticum and 77 
response to treatment.  Weiszfeiler et al reported that M. asiaticum in monkeys is 78 
resistant to streptomycin, isoniazid, p-aminosalicylate, and rifampicin but susceptible 79 
to cycloserine.(32) However the use of antituberculous therapy, including agents such 80 
as isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin and capreomycin 81 
yielded more encouraging results in humans, (5,27) with clinical response not 82 
correlating with in vitro susceptibilities.  Older fluoroquinolones, such as ofloxacin, 83 
have also been used, although M. asiaticum has higher Mean Inhibitory 84 
Concentrations (MICs) than other slow growing mycobacteria.(15)  85 
 86 
The aim of this study was to evaluate isolates of M. asiaticum in Queensland and 87 
describe incidence and epidemiology of disease, risk factors, clinical and radiological 88 
spectrum, treatments and outcome. 89 
 90 
METHODS 91 
 92 
We conducted a retrospective review of all cases that isolated Mycobacterium 93 
asiaticum in QLD between November 1989 and December 2007. In QLD all NTM 94 
isolates are speciated by a central reference laboratory – The QLD Mycobacterial 95 
Reference Laboratory (QMRL) and are notifiable to the Queensland Tuberculosis 96 
control centre (QTBCC). Letters and questionnaires are sent to the treating physicians. 97 
Data requested includes patient characteristics such as age, race, occupation, and 98 
exposures, clinical data such as risk factors, co-morbidities, clinical features, site of 99 
infection, microbiology and laboratory features, radiological features, treatment and 100 
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outcome. Physicians are asked whether they consider the organism to be responsible 101 
for clinical disease and are referred to guidelines to aid in this assessment. These 102 
guidelines were developed by the QTBCC and are in accordance with standard ATS 103 
criteria,(11) and were used to define disease for the purposes of the study. 104 
Participation in this survey is voluntary.  105 
 106 
Sputum samples were processed by a number of regional private laboratories and 107 
mycobacterial isolates referred onto the QMRL for speciation. All public hospital 108 
sputum specimens from the greater Brisbane area were transported directly to the 109 
QMRL and processed using 4% NaOH and phosphoric acid, and concentrated using 110 
centrifugation. A mycobacterium growth indicator tube (MGIT) (Becton 111 
Dickinson(BD)), was inoculated using 0.5 ml of sediment, and 0.25 ml was used to 112 
inoculate solid Lowenstein-Jensen slopes. Inoculated MGIT media were incubated at 113 
35oC in a BD BACTEC 960 machine until a positive signal was detected. Solid media 114 
was incubated and screened weekly for the presence of growth.  115 
 116 
To confirm the presence of mycobacterial species, a Zeihl-Neelson stain was 117 
performed, followed by a multiplexed PCR targeting the 16s rRNA region. This 118 
method is used routinely to discriminate between M. tuberculosis, M. avium. M. 119 
intracellulare, M. abscessus and M. species.(33) For those identified as M. species, 120 
prior to 2004, further identification was performed using a MAC GenProbe or 121 
phenotypic identification. In 2004, both 16sRNA sequencing and Hain Life Sciences 122 
GenoType Mycobacterium kit were introduced. The Hain Life Sciences 123 
GenoType Mycobacterium AS (additional species) kit was used to identify some 124 
isolates between 2004 and 2008. However, species identification was confirmed on all 125 
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isolates (including those pre 2004) by amplifying the hypervariable regions a and b 126 
outside the 16s region of the genome. This amplified product was sequenced using big 127 
dye terminator chemistry. Analysis was performed using both Genbank and RIDOM 128 
databases.  129 
  130 
Susceptibility testing in 1991 was performed using the Proportion Method on 7H10 131 
agar, with resistance defined as 1% of the proportion of the bacterial population 132 
resistant to the drug. Subsequently the BD BACTEC MGIT 960 method was used for 133 
streptomycin, rifampicin, isoniazid and ethambutol, following the manufacturer’s 134 
instructions. Clarithromycin was tested at concentrations of 4g/ml, 16g/ml and 135 
64g/ml in line with CLSI guidelines.  136 
 137 
RESULTS 138 
 139 
Patient characteristics and distribution 140 
 141 
Twenty four patients (11M 13 F) isolated M. asiaticum between 1989 and 2007 142 
(Figure 1). The mean age was 54.8 years. The biggest cluster of isolates (n=8) was 143 
centered on Townsville in Northern Queensland (Figure 2).  Fifty-eight percent of 144 
isolates were from sputum specimens, 21% were found in bronchial washings, 4% 145 
were found in both sputum and bronchial washings (Table 1), and 17% of isolates 146 
were from extrapulmonary sites (Table 2). Underlying chronic lung disease was 147 
present in 65% of patients with pulmonary isolates - namely COPD (40%), 148 
bronchiectasis (20%), lung cancer and cystic fibrosis (CF). One patient had possible 149 
past tuberculosis and another was on treatment for tuberculosis. Five of 20 patients 150 
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with pulmonary M. asiaticum isolated other NTM prior to, and four patients isolated 151 
other NTM after isolating M. asiaticum. Three patients isolated non NTM organisms 152 
at the same time. The most common NTM were MAC and unspeciated slow growers. 153 
Isolation of non NTM organisms was more frequent after isolation of M. asiaticum, 154 
the most common being Pseudomonas aeruginosa and Staphylococcus aureus. 155 
 156 
Significance.  157 
 158 
One patient had cavitary pulmonary disease and the other had disease in the setting of 159 
bronchiectasis, 2 had extrapulmonary disease (olecranon bursitis and lymphadenitis), 160 
6 had possible pulmonary disease and 2 had possible extrapulmonary disease 161 
(wound/soft tissue infections). The remaining isolates were not felt to be associated 162 
with NTM disease by the treating physician or there was insufficient information 163 
available to make a judgement.  164 
 165 
Pulmonary disease 166 
 167 
Two patients satisfied the QTBCC and ATS criteria for definite NTM disease due to 168 
M. asiaticum.  169 
Patient 1 was a 52 year old male, from Far North Queensland presenting in 1991 with 170 
a productive cough and weight loss, on a background of smoking related COPD. CXR 171 
showed left upper lobe cavitation. Four of five sputa were smear positive and all were 172 
culture positive for M. asaticum. He received ethambutol, rifampicin and isoniazid, 173 
for 12 months with pyrazinamide added for the first 2 months. In vitro susceptibilities 174 
showed susceptibility to clarithromycin, rifampicin 20mol/ml, rifabutin, ethambutol, 175 
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clofazamine and ciprofloxacin and resistance to rifampicin 5 and 10mol/ml. CXR 176 
showed clearing by 3 months and further clearing at 6 months. Sputum conversion 177 
occurred after 4 months of treatment. 178 
 179 
The second patient presented in late 1998 at the age of 73 with a lifetime history of 180 
chronic productive cough, and an episode of haemoptysis. Two of three sputum 181 
samples were smear positive for acid fast bacilli, 1 was smear negative and all 3 grew 182 
M. asiaticum. CXR showed nonspecific bronchial wall thickening, and CT chest 183 
revealed evidence of bronchiectasis involving the right middle lobe and the right 184 
lower lobe. Between 1998 and 2000, she had intermittent episodes of small volume 185 
haemoptysis and recurrent exacerbations partially responding to courses of 186 
ciprofloxacin. She was managed with sputum clearance techniques, chest 187 
physiotherapy and nebulised hypertonic saline during exacerbations, but no specific 188 
NTM therapy. Sputum cultures from February 2000 and June 2001 were heavily 189 
smear positive for AFBs, but no further identification was available.  A repeat CT 190 
however showed progression of the bronchiectasis with mild to moderate 191 
bronchiectasis in both lower lobes and lingula. Sputum specimens continued to grow 192 
M. asiaticum.  193 
 194 
In 2003 treatment was commenced with ethambutol, rifampicin, and clarithromycin. 195 
She developed a rash –attributed to ethambutol after rechallenge, and ciprofloxacin 196 
was substituted. Clarithromycin was changed to azithromycin, as it was perceived that 197 
the former was ineffective. In 2004 prothionamide was added because of progressive 198 
symptoms, and intermittent courses of ceftazidime were commenced for 199 
Pseudomonas infection. In 2005, rifampicin was ceased to simplify treatment. 200 
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Nebulised amikacin was trialed but resulted in dysphonia. Intravenous amikacin was 201 
therefore given thrice weekly for 8 weeks, in combination with minocycline 100mg/d 202 
and azithromycin 250 mg/d. In vitro susceptibilities were done retrospectively for the 203 
purpose of this study. The isolate was susceptible to ethambutol and clarithromycin, 204 
and resistant to rifampicin, isoniazid and streptomycin. The patient remained on oral 205 
treatment for 2 years, with good symptomatic response and sputum conversion. 206 
Treatment was ceased in 2007, however cough and sputum increased. The October 207 
2007 CT showed no extension of the bronchiectasis compared to 2006. As there had 208 
been 18 months of negative sputum cultures (except for one isolate of M. gordonae, 209 
regarded as a contaminant), it was felt her symptoms were most likely due to her 210 
underlying bronchiectasis. At the patients request azithromycin was recommenced 211 
thrice weekly. Sputum specimens now regularly culture Achromobacter xylosoxidans.  212 
 213 
Possible pulmonary disease 214 
 215 
All patients with possible pulmonary disease had underlying lung pathology, 216 
including COPD (n=2), CF (n=1), bronchiectasis (n=1) and lung cancer (n=2). All the 217 
patients with underlying COPD and lung cancer were current or past smokers. The CF 218 
and bronchiectasis patients were nonsmokers. (Table 3) 219 
 220 
Patients with the established risk factors of COPD and bronchiectasis had other NTM 221 
isolates prior to M. asiaticum, making it hard to determine whether M. asiaticum 222 
contributed to the pulmonary disease. The most common other NTM isolated was M. 223 
intracellulare. Others included M. avium, M. smegmatis, M. peregrinum, M. kubicae 224 
and M. gordonae.  225 
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 226 
Clinical features were non specific and included cough, haemoptysis, weight loss, and 227 
recurrent infective exacerbations. Radiological changes were mostly consistent with 228 
underlying disease and included progressive bronchiectasis, nodules >5mm and upper 229 
lobe opacity. None of the patients had cavitatory changes.  230 
 231 
Two of these six patients were treated for NTM disease presumed due to MAC, with 232 
M. asiaticum considered either a copathogen or contaminant. Drugs used included 233 
ethambutol, rifampicin, clofazimine, clarithromycin and ciprofloxacin. The duration 234 
of treatment was 18-24 months initially followed by further treatment if evidence of 235 
disease progression. One patient died despite treatment. NTM disease together with 236 
COPD was thought to be a contributory factor to his death. The other patient had 237 
received treatment for NTM disease prior to isolation of M. asiaticum, with no further 238 
treatment given afterwards. She had evidence of progressive disease with continued 239 
weight loss, and developed cor pulmonale. Both lung cancer patients received 240 
treatment for their lung cancer but no treatment for NTM disease.  241 
 242 
Extrapulmonary Isolates. 243 
 244 
The patient with olecranon bursitis has been previously reported.(6) He (patient 21) 245 
sustained a left elbow laceration in August 1988, and presented with olecranon 246 
bursitis in October 1989. It was initially deemed to be a low grade bursitis, and no 247 
treatment was given. By November 1989 there was persistent elbow inflammation. It 248 
was therefore aspirated and injected with methylprednisolone. In December 1989, it 249 
was again aspirated and he was commenced on flucloxacillin. Radiology showed no 250 
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evidence of osteomyelitis.  The aspirate was smear negative for acid fast bacilli, but 251 
M. asiaticum was grown. This was sensitive to cycloserine and prothionamide, and 252 
resistant to isoniazid, rifampicin and ethambutol. Around this time the patient moved 253 
from Townsville to a town just North of Melbourne. By January 1990 a sinus had 254 
developed. He received a second course of flucloxacillin, and the sinus was treated 255 
locally with H2O2 irrigation, povidone-iodine dressings and immobilization.  No 256 
specific antimycobacterial treatment was given. The wound started to heal slowly, and 257 
further swabs did not isolate mycobacteria.  258 
 259 
A four year old girl presented with submandibular lymphadenitis (patient 22) and an 260 
excision biopsy demonstrated multiple caseating granulomata; M. asiaticum was 261 
cultured. No further treatment was given. 262 
 263 
In both of the other 2 extrapulmonary cases M. asiaticum was cultured from 264 
nonhealing wounds. The first case (patient 23) presented with a non healing right foot 265 
wound thought to be from a coral cut. A wound swab grew M. asiaticum, but biopsy 266 
revealed a basal cell carcinoma infiltrating the deep dermis, and tissue culture grew a 267 
heavy growth of S. aureus. Histology of the surgically excised specimen, 2 months 268 
after isolation of M. asiaticum did not reveal evidence of mycobacterial infection.  269 
 270 
The second patient –am Irish tourist in North QLD presented with a left shin ulcer and 271 
a wound swab grew M. asiaticum. No further follow up was available as the patient 272 
returned to Ireland. 273 
 274 
DISCUSSION 275 
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 276 
Although data in the literature is limited, it has already been established that M. 277 
asiaticum is a pathogen that can be associated with human disease. However the 278 
nature, extent and spectrum of disease have not been very well described. Data on 279 
treatment and response to treatment is also lacking and physicians often have to rely 280 
on “expert opinion” when treating disease due to this slow growing mycobacterium. 281 
To our knowledge this is the largest series of M. asiaticum isolates described in the 282 
literature to date.  283 
 284 
Although rare, our study reveals a relatively high incidence of M. asiaticum isolates in 285 
Queensland. NTM disease as a group seems to be more prevalent in warmer climates. 286 
In the 2000 national NTM survey, Queensland and the Northern territory rated highest 287 
among all Australian states and territories for the incidence of NTM disease, with 3.8 288 
and 4.1 reported cases per 100.000 population respectively.(12) NTM causing non-289 
pulmonary disease was also found to be prevalent in Queensland.(4, 13) The ideal 290 
growth conditions for many NTM include a temperature between 10 and 45°C. With 291 
the Tropic of Capricorn running through the centre of QLD, an ideal climate for NTM 292 
growth exists year round. Rates of disease in Victoria and New South Wales, more 293 
southern states of Australia in 2000, were 1.3 and 0.78 per 100000 respectively. (12) 294 
Distribution data for M. asiaticum from our study confirm the observations of 295 
Blacklock (5) where 3 of 5 patients in that study lived around the Tropic of Capricorn, 296 
1 was born in the Tropic and moved to Southern Queensland and 1 lived 600km north 297 
of the Tropic. Most of our isolates came from in and around this area, mostly from 298 
Townsville.  299 
 300 
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An important reservoir could be Queenland’s potable water supplies. In 1980 Tuffley 301 
et al sampled water from rainwater tanks in Central Queensland. NTM were isolated 302 
in 32 of 141 samples.(28) More recent sampling has identified mycobacteria in >70% 303 
of Brisbane sites sampled; however M. asiaticum was not isolated. Sampling in 304 
Townsville and Rockhampton however has not been performed.  In a Czech study, the 305 
authors reported that there were seasonal variations in the occurrence of mycobacteria 306 
in drinking water, and they attributed this to a change in water temperature.(14) Given 307 
Queensland’s climate, Queensland’s water distribution systems would provide the 308 
ideal environment for NTM growth, including M. asiaticum.  309 
 310 
Risk factors for M. asiaticum were similar to those observed for other NTM species, 311 
with COPD and bronchiectasis being the most commonly observed pre-existing 312 
conditions in pulmonary cases. The association between bronchiectasis and NTM 313 
disease has been well described, and bronchiectasis is now recognized both as a cause 314 
and effect of NTM disease.(3) In their 2005 series, Koh et al reported that 1/3 of 315 
patients with bilateral bronchiectasis and bronchiolitis on CT had NTM disease. 316 
Furthermore invasive NTM disease has been associated with slow progression of 317 
bronchiectasis without cavitation on HRCT.(20, 26) The Lady Windermere syndrome 318 
first described in 1992 denotes fibronodular bronchiectasis most commonly occurring 319 
in thin women >60 years old involving the right middle lobe and lingula.(21)  This 320 
form of bronchiectasis without cavitation is becoming increasingly recognized as an 321 
important pattern of NTM pulmonary disease.  The M. asiaticum cases described 322 
previously by Blacklock both had cavitatory disease(5) whereas the case described by 323 
Taylor et al had nodular disease.(27)  In our series one patient had cavitary disease 324 
(patient 1) and at least 2 patients could well fit the pattern of Lady Windermere 325 
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syndrome (patients 2 and 6). Both of them developed radiological evidence of 326 
progression of the bronchiectasis, in the presence of NTM including M. asiaticum.  327 
 328 
Although lung cancer has not previously been considered a predisposing condition for 329 
NTM disease, it is worth noting that 2 patients with possible M.asiaticum disease in 330 
our study had non small cell lung cancer (patients 7 and 8). They were classed as 331 
having possible NTM disease on the basis that the specimen was a bronchial washing 332 
that is normally regarded as sterile. The low number of patients in this study precludes 333 
us from reaching any conclusions regarding the association between lung cancer and 334 
M. asiaticum disease/colonization. It is hard to determine the pathogenicity of NTM 335 
in these cases. Radiological changes are not very helpful if the focus of infection is 336 
within or in the same lobe as the tumor. Tamura et al reported on the coexistence of 337 
lung cancer and active pulmonary mycobacteriosis. In their series 11/61 patients with 338 
lung cancer and coexistent mycobacteriosis had foci in the same lobe. Five of these 339 
were NTM infections and in 3 cases the focus of mycobacterial infection was not 340 
separately identifiable.(25) It is difficult to make the decision of whether to treat the 341 
NTM in these cases. More often than not, as was the case in our series, treatment for 342 
the pulmonary malignancy takes priority and the NTM is left untreated. Long term 343 
outcomes are also hard to assess as survival is often limited.  344 
 345 
In our series two patients met the QTBCC/ATS criteria for definite pulmonary 346 
disease. Clinical features were non specific, in line with what would be expected for 347 
NTM disease. In the first case sputum conversion and cure was achieved with 348 
standard TB treatment extended to 12 months. In the second patient remission was 349 
achieved with amikacin thrice weekly for 8 weeks, azithromycin 250mg/day and 350 
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minocycline 100mg/day (for 2 years). It was hard to assess response to standard 351 
ethambutol / rifampicin / clarithromycin regime as the ethambutol was not tolerated. 352 
However clarithromycin/ rifampicin / ciprofloxacin were not effective in controlling 353 
symptoms or converting sputum cultures to negative, even with the addition of 354 
prothionamide. The duration of treatment for this patient was difficult to determine. 355 
Symptoms recurred when there was an attempt at stopping treatment but it was felt 356 
that the anti-inflammatory properties of azithromycin was controlling symptoms in 357 
the last year of treatment as cultures have been repeatedly negative for 358 
mycobacteria.(1, 10) 359 
 360 
It has previously been noted that in vitro sensitivities do not correlate well with 361 
clinical response in NTM disease.(5, 27) It is therefore difficult to assess the relevance 362 
of the susceptibilities performed.   In previously published case reports, patients 363 
responded to regimens using rifampicin/ isoniazid/ ethambutol/ streptomycin, 364 
ethambutol/rifampicin and rifampicin/ ethambutol/ capreomycin/ pyrazinamide.(5, 365 
27) Although these observations are useful, it is hard to give specific treatment 366 
recommendations given the relatively small number of M. asiaticum cases in the 367 
literature.  368 
 369 
It is also interesting to note the change in respiratory flora after isolation of M. 370 
asiaticum. We hypothesize that the damage done to the lung by active NTM disease 371 
would set the stage for colonization by other organisms. This phenomenon appears to 372 
be common to pulmonary disease across all NTM species.  373 
 374 
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Extrapulmonary infections in this group included lymphadenitis in a child and 375 
olecranon bursitis following an elbow laceration. NTM have long been recognized as 376 
a cause of cervical lymphadenitis in children.(17, 30) The commonest NTM species 377 
involved is M. avium complex. Others include M. kansasii, M. scrofulaceum, M. 378 
xenopi, and M. chelonae. Lymphadenitis due to M. asiaticum has not been previously 379 
reported in humans, although a case report exists of lymphadenitis due to M. 380 
asiaticum in a red-handed tamarin.(24)  NTM lymphadenitis is commonly treated 381 
with local excision, with excellent response as was the case with our patient. Bursitis 382 
has been previously reported with M. kansasii, M. szulgai, M. avium–intracellulare 383 
and M. marinum.(2, 9, 16, 18, 19, 22, 23, 29) Cases are usually treated with a 384 
combination of surgery and appropriate antimycobacterial agents. To our knowledge 385 
the patient with olecranon burstis is the only reported case of bursitis secondary to M. 386 
asiaticum.(6) He responded to nonspecific treatment including drainage, regular 387 
dressings and arm rest.  388 
 389 
Our study had several limitations – i) it is a relatively small series, with only one 390 
definite case of pulmonary disease attributable to infection with M. asiaticum, ii) 391 
because our data collection relied on physicians returning questionnaires, some of the 392 
data was missing or incomplete, iii) although physicians had access to guidelines to 393 
assess the clinical significance of M. asiaticum, the assessment was made by the 394 
individual physicians who would have varying levels of exposure to and experience 395 
with patients with NTM infections.  396 
 397 
Despite the limitations of a small case series, we have made a number of 398 
epidemiologically and clinically relevant observations. M. asiaticum seems to be more 399 
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prevalent in a warm climate such as that of Queensland. It is often a 400 
colonizer/contaminant, but can be responsible for pulmonary disease including non- 401 
cavitary disease. It can also be responsible for childhood lymphadenitis and soft tissue 402 
infections. Risk factors, clinical and radiological features are largely similar to those 403 
observed for other NTM species. Treatment for pulmonary disease is challenging and 404 
larger series are needed to enable specific treatment recommendations. Local excision 405 
seems sufficient for childhood lymphadenitis, as observed for other NTM species. 406 
Bursitis may also respond to local measures, and the isolation of M. asiaticum does 407 
not mandate specific treatment. 408 
409 
 410 
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Figure 1. Number of patients with isolates according to year of first isolate.  

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Table 1. 
Clinical characteristics of 20 patients with pulmonary M. asiaticum isolates. 
ID Age/ 
Sex 
Specimen  
type 
M. asiaticum  
microbiology 
Risk factors/  
comorbidities 
Isolates pre M. 
asiaticum 
Isolates post 
M. asiaticum 
Pulmonary 
disease 
1 52/M Sputum S+ C+ (4/5) 
S- C+ (1/5) 
Asthma/ COPD Nil Nil Present 
2 73/F Sputum  S ++,  3/3C +; 
subsequent  
multiple +ve 
cultures 
BE, COPD PsA Other NTM, 
Aspergillus, 
Acinetobacter, 
A. xylosoxidans  
Present  
3 79/M Sputum S- C + (10/04);  
S- C + (2/05) 
COPD, previous 
Dukes C bowel 
cancer 
NTM S.aureus, S. 
maltophilia, 
PsA  
Possible 
4 55/M Sputum S- C+ COPD Other NTM* PsA Possible  
5 28/F Sputum S- C+ CF, ABPA Other NTM, 
PsA, Asp, S.  
aureus 
PsA, S. aureus  Possible  
6 77/F Sputum S n/a  C+ BE, GORD Other NTM, H. 
influenzae 
PsA, Proteus 
mirabilis  
Possible 
7 85/M Br wash S- C+ NSCLC Nil Nil Possible 
8 72/M Br wash S- C+ HBV, NSCLC Nil Nil Possible 
9 52/M Br wash S- C+ None Nil Nil No 
10 38/M Sputum S n/a ,  C+ Non-IV drug use Nil Nil No 
11 68/M Sputum S- C+ DM, COPD Nil NTM No 
12 62/F Sputum S- C+ TB M.tuberculosis Nil No 
13 46/F Sputum S- C+ 
 
Nil Nil No 
14 77/F Br wash S- C+ BE, DM Nil Nil No 
15 83/M Br wash S- C+ Asthma/COPD Nil MAC, S. 
aureus, Asp 
No 
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 A. xylosoxidans= Achromobacter xylosoxidans; Asp=Aspergillus spp; BE=bronchiectasis; Br wash=bronchial washings; C=culture; CF=cystic fibrosis; COPD=chronic 
obstructive pulmonary disease; Cz=ceftazidime; DM= diabetes mellitus; F=female; GERD=gastro-esophageal reflux disease; HBV= hepatitis B virus; M= male; MAC= 
Mycobacterium avium complex; n/a=not available; NSCLC=non-small cell lung cancer; NTM=non tuberculous mycobacteria; PsA= Pseudomonas aeruginosa; S=smear; S. 
aureus=Staphylococcus aureus; S. maltophilia=Sternotrophomonas maltophilia. 
                                                 
*
 The most common other NTM were MAC and unspeciated slow growers. Others included M. smegmatis, M. gordonae, M. kubicae and M. 
peregrinum 
16 76/F Sputum  S++  C  + DM NTM N/A  
17 52/M Br wash/ 
Sputum 
S- C+ (2/04); 
S- C+ (10/04) 
COPD NTM S. maltophilia, 
PsA, S. aureus  
No 
18 37/F Sputum  S- C+ Alcoholism,  
COPD, BE 
Nil Nil No 
19 25/M Sputum S+ C+.  Nil Nil No 
20 84/M Sputum S- C+ ? Previous TB Nil Nil No 
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 Table 2. 
 
Clinical characteristics, treatment and outcome of 4 patients with non pulmonary NTM 
isolates 
 
 
BCC=basal cell carcinoma; Bx=biopsy; C=culture;  F=female; f/u=follow up; L=left; M= male; n/a=not available; 
R=right; RML=right middle lobe; Rx=treatment;. aureus=Staphylococcus aureus. 
 
ID Age/ 
sex 
Risk 
factors 
Specimen 
type 
M. asiaticum 
microbiology 
Other  
isolates 
Disease Treatment Outcome 
21 24/M Elbow  
laceration 
Elbow  
aspirate 
S- C+ Nil Olecranon 
bursitis 
Aspiration, 
local steroid, 
flucloxacillin 
Developed 
sinus – 
healed 
with local 
Rx 
   22 4/F Nil Submandibul
ar node 
S n/a, C+ Nil Lymph- 
adenitis 
Excised Healed 
23 45/M Pre-
existing 
wound 
R foot swab S- C+ S.aureus  
on 
tissue 
culture 
Possible 
wound 
infection 
Bx – BCC - 
excised 
Good 
response 
24 22/M Pre-
existing 
wound 
Wound 
swab L shin 
S n/a, C+ Nil Possible 
wound 
infection 
Lost to f/u Lost to f/u 
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Table 3. 
Clinical features, treatment and outcome of 6 patients with possible pulmonary disease 
ID Smoker Clinical features Radiology Treatment  Outcome/ comments 
3 Yes SOB on exertion, 
minimal sputum 
Nodules >5mm, small 
RUL nodular opacity, 
unchanged on serial 
Xrays, presumed 
granuloma 
Not treated Alive – ICU admission 
with type 1 respiratory 
failure - 2008 
4 Yes n/a n/a 18 month Rx for 
NTM – no details 
specified 
Deceased (NTM disease 
+ COPD) 
5 No Recurrent 
infective 
exacerbations 
Extensive bilateral BE Not treated for M. 
asiaticum 
Alive 
6 No Cough, anorexia, 
weight loss 
BE RML, progressed to 
fibrotic and airspace 
change in lingula, LUL, 
RUL and RML   
Not treated for M. 
asiaticum, previous 
treatment for other 
NTM 
M. asiaticum isolated 
late in course of NTM 
disease. Developed cor 
pulmonale. 
7 Yes n/a Lung mass XRT Alive 
8 Yes n/a RUL mass Chemoradiation, 
excision of 
cerebellar metastasis 
Repeat FOB: S- C- 
BE=bronchiectasis; C=culture; COPD=chronic obstructive pulmonary disease; FOB=fibreoptic bronchoscopy; LUL= left upper 
lobe; n/a=not available; NTM=non tuberculous mycobacteria; RML=right middle lobe; RUL=right upper lobe; Rx=treatment; 
S=smear; SOB=shortness of breath; XRT=radiation treatment.  
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